Cited by 727Alzheimer's disease research and treatmentsHistone Deacetylase Inhibitors ResearchMemory and Neural Mechanisms

Inhibitors of Class 1 Histone Deacetylases Reverse Contextual Memory Deficits in a Mouse Model of Alzheimer's Disease

Open access
Kilgore, Mark, Miller, Courtney A, Fass, Daniel M, Hennig, Krista M, Haggarty, Stephen J, Sweatt, J David, Rumbaugh, Gavin·2010·Neuropsychopharmacology

Abstract

Alzheimer's disease (AD) is a neurodegenerative disorder characterized clinically by cognitive impairments that progress to dementia and death. The earliest symptoms of AD present as a relatively pure deficit in memory retrieval. Therefore, drug treatments that intervene in the early stages of AD by rescuing memory deficits could be promising therapies to slow, or even reverse progression of the disease. In this study, we tested the potential of systemic histone deacetylase inhibitor (HDACi) treatment to rescue cognitive deficits in a mouse model of AD. APPswe/PS1dE9 mice showed pronounced contextual memory impairments beginning at 6 months of age. Chronic HDACi injections (2-3 weeks) did not alter contextual memory formation in normal mice, but had profound effects in transgenic animals. Injections of sodium valproate, sodium butyrate, or vorinostat (suberoylanilide hydroxamic acid; Zolinza) completely restored contextual memory in these mutant mice. Further behavioral testing of the HDACi-treated transgenic mice showed that the newly consolidated memories were stably maintained over a 2-week period. Measurement of the HDAC isoform selectivity profile of sodium valproate, sodium butyrate, and vorinostat revealed the common inhibition of class I HDACs (HDAC1, 2, 3, 8) with little effect on the class IIa HDAC family members (HDAC4, 5, 7, 9) and inhibition of HDAC6 only by vorinostat. These preclinical results indicate that targeted inhibition of class I HDAC isoforms is a promising avenue for treating the cognitive deficits associated with early stage AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/npp.2009.197

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Kilgore, M., Miller, C. A., Fass, D. M., Hennig, K. M., Haggarty, S. J., Sweatt, J. D., & Rumbaugh, G.
Affiliations
  • University of Alabama at Birmingham (US)
  • Broad Institute (US)
Corresponding author
Rumbaugh, Gavin
Venue
Neuropsychopharmacology
Published
2009-12-09
Volume
35
Issue
4
Pages
870-880
ISSN
  • 0893-133X (ISSN-L)
  • 1740-634X
OpenAlex
W2090054406
Cited by
727
References
8
Citations by year
2026: 32 · 2025: 34 · 2024: 43 · 2023: 31 · 2022: 25 · 2021: 33 · 2020: 41 · 2019: 30 · 2018: 53 · 2017: 48 · 2016: 51 · 2015: 40 · 2014: 68 · 2013: 68 · 2012: 58
FWCI
28.81
Type
journal article
Language
en
Open access
Locations
  • Neuropsychopharmacology (publishedVersion)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Brain Research Foundation
  • American Health Assistance Foundation
  • McKnight Foundation
  • Evelyn F. McKnight Brain Research Foundation
  • Stanley Medical Research Institute
  • National Alliance for Research on Schizophrenia and Depression
  • National Institute of Mental Health
  • National Institute on Drug Abuse (R01DA028301, R00DA024761)
  • National Institute of Neurological Disorders and Stroke
Topics
  • Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
  • Life Sciences › Neuroscience › Cognitive Neuroscience › Memory and Neural Mechanisms
Keywords
Alzheimer's disease, histone deacetylase inhibitors, class I HDACs, contextual memory, memory consolidation, APP/PS1 mice, valproic acid, sodium butyrate, vorinostat, HDAC isoform selectivity, cognitive impairment
MeSH terms
Alzheimer Disease, Analysis of Variance, Animals, Conditioning, Classical, Disease Models, Animal, Enzyme Inhibitors, Fear, Female, Hippocampus, Humans, Male, Memory Disorders, Mice, Inbred C57BL, Mice, Transgenic, Amyloid beta-Protein Precursor, Mice, Presenilin-1, Histone Deacetylase 1, In Vitro Techniques

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review